Syndax Pharmaceuticals Inc (SNDX)
20.81
+0.37
(+1.81%)
USD |
NASDAQ |
Apr 19, 16:00
20.81
0.00 (0.00%)
After-Hours: 18:26
Syndax Pharmaceuticals Free Cash Flow (Quarterly): -41.35M for Dec. 31, 2023
Free Cash Flow (Quarterly) Chart
Historical Free Cash Flow (Quarterly) Data
Date | Value |
---|---|
December 31, 2023 | -41.35M |
September 30, 2023 | -44.65M |
June 30, 2023 | -35.37M |
March 31, 2023 | -39.23M |
December 31, 2022 | -22.89M |
September 30, 2022 | -28.54M |
June 30, 2022 | -40.31M |
March 31, 2022 | -41.93M |
December 31, 2021 | 100.71M |
September 30, 2021 | -24.94M |
June 30, 2021 | -24.04M |
March 31, 2021 | -22.59M |
December 31, 2020 | -15.63M |
September 30, 2020 | -18.30M |
June 30, 2020 | -21.41M |
March 31, 2020 | -15.92M |
December 31, 2019 | -12.73M |
September 30, 2019 | -8.529M |
June 30, 2019 | -12.52M |
March 31, 2019 | -16.83M |
December 31, 2018 | -15.06M |
September 30, 2018 | -18.47M |
Date | Value |
---|---|
June 30, 2018 | -15.15M |
March 31, 2018 | -20.04M |
December 31, 2017 | -12.76M |
September 30, 2017 | -10.22M |
June 30, 2017 | -11.80M |
March 31, 2017 | -12.67M |
December 31, 2016 | -10.42M |
September 30, 2016 | -11.50M |
June 30, 2016 | -6.963M |
March 31, 2016 | -6.536M |
December 31, 2015 | -4.326M |
September 30, 2015 | -5.195M |
June 30, 2015 | -4.001M |
March 31, 2015 | 11.04M |
December 31, 2014 | -3.475M |
September 30, 2014 | -2.602M |
June 30, 2014 | -3.804M |
March 31, 2014 | -4.512M |
December 31, 2013 | -2.786M |
September 30, 2013 | -2.135M |
June 30, 2013 | -0.927M |
March 31, 2013 | -1.485M |
Free Cash Flow Definition
Free cash flow measures the amount of cash left over from a time period after all operational and working capital payments are made. Free cash flow is an important metric because it allows you to view the amount actual cash is available to the company. Free cash flow is also commonly used in valuation calculations like the discounted cash flow valuation model.
Free Cash Flow (Quarterly) Range, Past 5 Years
-44.65M
Minimum
Sep 2023
100.71M
Maximum
Dec 2021
-19.48M
Average
-22.89M
Median
Dec 2022
Free Cash Flow (Quarterly) Benchmarks
SpringWorks Therapeutics Inc | -60.40M |
Alnylam Pharmaceuticals Inc | -45.10M |
Geron Corp | -41.00M |
Ionis Pharmaceuticals Inc | 32.89M |
Madrigal Pharmaceuticals Inc | -80.97M |